Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari Fischer(Cornell University), Dingcheng Gao(Cornell University), Jianting Sheng(Houston Methodist), Sharrell Lee(Cornell University), Nasser K. Altorki(Cornell University), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Vivek Mittal(Cornell University), Robert F. Schwabe(Columbia University), Seongho Ryu(Soonchunhyang University), Anna Durrans(Cornell University), Fuhai Li(Washington University in St. Louis), Hyejin Choi(Cornell University), Juliane S. Troeger(Columbia University), Tina El Rayes(Cornell University), Stephen T.C. Wong(Cornell University)
Cited by 1,793
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
A molecular single-cell lung atlas of lethal COVID-19
|Nature|2021|735